Skip to main content

Table 4 Final Multivariable Model for pirfenidone (versus nintedanib) use

From: Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Characteristic:

Coefficient

Odds ratio

95% Confidence Interval

P-value

Days since diagnosis (per unit increase in log days)

0.071

1.074

0.998–1.155

0.0576

Anticoagulant use

0.919

2.507

1.374–4.575

0.0028

Coronary artery disease

0.588

1.800

1.216–2.664

0.0034

Pulmonary hypertension

0.724

2.062

1.000–4.249

0.0499

DLCO (percent-predicted, per 10%)

0.142

1.153

1.033–1.287

0.0115

(Patient) Clinical trial participation in last 12mo.

0.927

2.526

1.553–4.111

0.0002

Midwest region (compared to South)

0.502

1.652

0.983–2.775

0.0579

Northeast region (compared to South)

0.061

1.062

0.658–1.715

0.8038

West region (compared to South)

−0.114

0.892

0.481–1.655

0.7175

  1. Abbreviations: Idiopathic Pulmonary Fibrosis (IPF); diffusion limitation for carbon monoxide (DLCO); months (mo)
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us